News | Press releases & other news
Press releases
Aug 26, 2026
Lytix Biopharma Q2 2026: FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma, Marking Defining MilestoneRead more...Aug 26, 2026
FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk MelanomaRead more...Aug 26, 2026
Lytix to Partner with Leading Investigator on ALETTA Study Testing Ruxotemitide in Combination with Ipilimumab and Nivolumab in Early-stage Resectable MelanomaRead more...Aug 20, 2026
Lytix Biopharma: Invitation to the Q2 2026 Results PresentationRead more...Aug 18, 2026
Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business OfficerRead more...Jul 23, 2026
Lytix Biopharma ASA: Grant of share options to management and key personnelRead more...Jun 1, 2026
Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with PembrolizumabRead more...May 20, 2026
Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning AdvancesRead more...May 15, 2026
Lytix Biopharma: Invitation to the Q1 2026 Results PresentationRead more...May 5, 2026
New Phase II Study Data from Lytix Biopharma's Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell CarcinomaRead more...Apr 21, 2026
Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026Read more...Apr 20, 2026
Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced MelanomaRead more...Apr 16, 2026
Lytix Biopharma ASA - Conversion to public limited liability company and name change registeredRead more...Apr 14, 2026
Lytix Biopharma AS: Minutes from Annual General MeetingRead more...Apr 9, 2026
Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONSRead more...Apr 7, 2026
Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of GrowthRead more...Mar 25, 2026
Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026Read more...Mar 23, 2026
Lytix Biopharma AS: Annual Report for 2025Read more...Mar 17, 2026
Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026Read more...Feb 24, 2026
Lytix Biopharma AS - New share capital registeredRead more...
For the full archive of regulatory news releases, visit Oslo Børs NewsWeb.
Visit Oslo Børs NewsWeb